Pricing Log in Create free account
Friday 6 November 2026 Export PRGO’s income statement to Excel — free account

Perrigo Company plc

PRGO Healthcare Drug Manufacturers Specialty & Generic

Perrigo Company plc’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 2.75% from fiscal 2024.

Revenue
−5.24%
EPS
−494.6%
Free cash flow
+138.5%
Total debt
−9.62%

Quarter to September 2026, against a year earlier

15.66 0.17 −1.07%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−7.2×
Dividend yield
7.41%
F-score
4/9
Altman Z
−0.08
Beneish M
−3.51
Dividend safety
16/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.89%

Capital & Financial Ratios $m

Size
Market Cap 2,180.00
Revenue ttm 4,090.20
Net income ttm (1,769.70)
Free cash flow ttm 168.20
Net debt Q 2,857.50
Valuation
P/E 0.00
Forward P/E (7.24) (negative: loss-making)
Price / sales 0.53
Forward P/S Powerpack
Price / FCF 12.39
Price / book 0.89
Financial health
Current ratio Q 2.35 (at or above 1.5: strong)
Debt / equity Q 1.35
Interest coverage Q 0.61
Growth
Revenue growth Q −5.24% (below 0%: shrinking)
Operating income growth Q −68.18% (below 0%: shrinking)
EPS, this year −16.88% (below 0%: weak)
EPS, next year A +1.17%
Revenue, next year A −4.68% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A −4.84% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.2×, against a ten-year median of 2.0×; over the ten years it ranged from 1.0× in 2026 to 10.1× in 2016.
P/S against its own 10 years 8.65%
10-year low 10-year high
P/B against its own 10 years 25.78%
10-year low 10-year high
EV/Sales against its own 10 years 8.58%
10-year low 10-year high
EV/FCF against its own 10 years 51.99%
10-year low 10-year high

Dividends raised every year since 2017

Yield
7.41%
Annual rate
1.16
Payout ratio
—
Growth, 2017–25
+7.72%/yr
  1. 0.64 ’17
  2. 0.76 ’18 +19
  3. 0.82 ’19 +8
  4. 0.90 ’20 +10
  5. 0.96 ’21 +7
  6. 1.04 ’22 +8
  7. 1.09 ’23 +5
  8. 1.10 ’24 +1
  9. 1.16 ’25 +5
  10. 1.16 ’26e +0
paid forecast change on the year, % Powerpack

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 751 559 532 437
Receivables 740 642 613 686
Inventory 1,141 1,082 1,149 1,014
Other — — 273 —
2,833 2,482 2,797 2,402
2023 2024 2025 Q'26
Payables 478 495 475 391
ST’ Debt 441 36 37 11
Other — — 27 —
1,586 1,044 1,013 1,020

Compound Annual Growth %

10y 5y 3y
Sales 4.92% 0.79% (1.51%)
Cash Flow 1.73% (17.82%) (8.10%)
Earnings 0.00% 0.00% 0.00%
Book Value (11.63%) (12.29%) (15.37%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.56 Actual 0.60

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.80 0.77 Miss by 0.03
Q1 FY26 0.39 0.43 Beat by 0.04
Q2 FY26 0.31 0.50 Beat by 0.19
Q3 FY26 0.56 0.60 Beat by 0.04
Q4 FY26 0.68 — Reports 25 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (2.87) 0.53 (0.20) — —
’25 (0.05) (0.06) 0.05 (10.22) (10.29)
’24 0.01 (0.79) (0.15) (0.32) (1.25)
’23 (0.02) 0.06 0.10 (0.24) (0.09)
’22 (0.02) (0.48) (0.37) (0.09) (1.04)
’21 0.28 (0.43) (0.44) 0.24 (0.52)
’20 0.77 0.44 (1.13) (1.29) (1.19)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 969 1,023 989 — —
’25 1,044 1,056 1,043 1,110 4,253
’24 1,082 1,066 1,088 1,138 4,373
’23 1,182 1,193 1,124 1,157 4,656
’22 1,075 1,122 1,100 1,155 4,452
’21 1,010 981 1,043 1,105 4,139
’20 1,083 949 1,003 1,053 4,088
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (114) 83 96 — —
’25 (64) 76 52 175 239
’24 (1) 10 42 313 363
’23 19 53 125 209 406
’22 79 (17) 59 186 307
’21 0 (82) 344 (105) 156
’20 172 291 63 110 636
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (126) 68 79 — —
’25 (88) 58 33 151 151
’24 (25) (18) 49 281 288
’23 (2) 50 94 186 328
’22 83 (43) 14 186 240
’21 (44) (105) 303 (146) 8
’20 140 265 20 45 470
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 5,281 4,946 4,732 3,870 4,088 4,139 4,452 4,656 4,373 4,253 4,090 (2.4%) 4,054 4,084 4,140 (0.9%)
Gross margin, % 38.86 40.02 38.71 37.05 36.57 34.22 32.69 36.09 35.27 35.14 32.33 (3.7) pt
EBT (4,848) 280 291 148 6 259 (139) (8) (81) (1,298) (1,653) (13.6%)
EBT margin, % (91.81) 5.66 6.14 3.82 0.14 6.25 (3.12) (0.18) (1.85) (30.52) (40.41) +61.3 pt
Net income (4,013) 120 131 146 (163) (69) (141) (13) (172) (1,425) (1,770) (10.9%)
Per share, $
Per share, $ Revenue 36.85 34.76 34.34 28.46 30.04 30.98 33.10 34.41 31.83 30.71 29.34 (2.0%)
Earnings (28.01) 0.84 0.95 1.07 (1.19) (0.52) (1.04) (0.09) (1.25) (10.29) (12.75) (10.5%)
Cash flow 4.57 4.91 4.30 2.85 4.67 1.17 2.28 3.00 2.64 1.72 1.73 (10.3%)
Capex 1.73 (0.01) (0.65) (0.99) (1.22) (1.11) (0.50) (0.57) (0.55) (0.63) (0.52) n/m
Free cash flow 6.30 4.90 3.66 1.86 3.45 0.06 1.78 2.42 2.09 1.09 1.21 (17.7%)
Book value 41.57 43.36 41.13 42.68 41.55 38.56 36.00 35.24 31.44 21.19 17.51 (7.2%)
Shares, m 143 142 138 136 136 134 135 135 137 139 139 (0.4%)
Valuation, ×
Valuation, × P/E 0.00 106.77 41.22 47.83 0.00 0.00 0.00 0.00 0.00 0.00 0.00 19.6
P/S 2.35 2.58 1.13 1.82 1.49 1.26 1.06 0.96 0.81 0.45 0.53 1.4
P/B 2.08 2.07 0.94 1.21 1.08 1.01 0.98 0.94 0.82 0.66 0.89 1.2
EV/Sales 3.33 3.12 1.70 2.59 2.21 1.66 1.85 1.68 1.51 1.18 1.23 2.1
EV/FCF 19.47 22.11 15.93 39.69 19.20 856.58 34.38 23.81 22.91 32.83 28.61 108.7
Cash, $m
Cash, $m Operating cash flow 655 699 593 388 636 156 307 406 363 239 241 (10.6%)
Capex 248 (1) (89) (135) (166) (148) (68) (77) (75) (88) (72) n/m
Free cash flow 902 698 504 253 470 8 240 328 288 151 168 (18.0%)
Balance, $m
Balance, $m Working capital 969 1,384 1,365 1,395 1,752 2,272 1,606 1,247 1,438 1,785 1,382 +7.0%
Net debt 5,175 2,663 2,691 3,015 2,933 1,656 3,506 3,322 3,059 3,109 2,858 (5.5%)
Shareholders’ equity 5,958 6,171 5,668 5,804 5,655 5,152 4,842 4,768 4,319 2,936 2,440 (7.6%)
Returns, %
Returns, % ROA (24.16) 0.94 1.16 1.31 (1.43) (0.63) (1.31) (0.12) (1.68) (15.68) (20.15) +8.5 pt
ROIC (11.23) 4.23 1.77 1.24 1.93 3.77 0.59 1.17 0.96 (11.60) (19.03) (0.4) pt
ROE (49.96) 1.97 2.21 2.55 (2.84) (1.28) (2.81) (0.26) (3.78) (39.29) (51.39) +10.7 pt
People
People Employees 12,800 10,400 10,600 11,200 11,500 9,900 8,900 9,140 8,379 8,100 — (5.0%)
Revenue/emp, $m 0.41 0.48 0.45 0.35 0.36 0.42 0.50 0.51 0.52 0.53 — +2.7%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Perrigo Company plc vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RGC Regencell Bioscience Holdings Limited $2.6B — (loss-making) — — — +57.15% (above 0%: growing) 0.00% — Compare
HCM HUTCHMED (China) Limited Sponsored ADR $2.5B — (loss-making) — +510.07% (above 0%: growing) +419.25% (above 0%: growing) +113.21% (above 0%: growing) 60.90% 0.00% Compare
XERS Xeris Biopharma Holdings, Inc. $2.4B — (loss-making) — (loss-making) +44.16% (above 0%: growing) +1,478.95% (above 0%: growing) +93.18% (above 0%: growing) 88.41% 15.78% Compare
PRGO Perrigo Company plc $2.2B — (loss-making) — (loss-making) −5.24% (below 0%: shrinking) n/m +138.48% (above 0%: growing) 32.45% 2.34%
TRLV Trulieve Cannabis Corp. $2.1B — (loss-making) — (loss-making) −20.12% (below 0%: shrinking) n/m +24.49% (above 0%: growing) 64.30% 0.00% Compare
PBH Prestige Consumer Healthcare Inc. $2.1B 13.7× 11.7× +22.69% (above 0%: growing) −38.37% (below 0%: shrinking) −38.18% (below 0%: shrinking) 51.30% 24.00% Compare
BCRX BioCryst Pharmaceuticals, Inc. $2.0B — (loss-making) — (loss-making) +13.11% (above 0%: growing) +150.00% (above 0%: growing) −18.69% (below 0%: shrinking) 99.13% 29.58% Compare
ALVO Alvotech $1.8B — (loss-making) 111× +2,310.95% (above 0%: growing) −99.51% (below 0%: shrinking) −496.58% (below 0%: shrinking) 56.47% 9.14% Compare
ANIP ANI Pharmaceuticals, Inc. $1.6B 13.3× 14.3× +27.64% (above 0%: growing) +29.41% (above 0%: growing) +85.49% (above 0%: growing) 61.64% 18.01% Compare
Median of peers $2.1B — 14.3× +27.64% +89.71% +40.82% 61.27% 15.78%

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 20 March 2026

Ownership

Directors and executive officers, together 0.40%
T. Rowe Price Associates, Inc.1307 Point Street, Baltimore, MD 12.30%
BlackRock, Inc.50 Hudson Yards, New York, NY 11.60%
The Vanguard Group100 Vanguard Blvd., Malvern, PA 10.90%
Fuller & Thaler Asset Management, Inc.411 Borel Avenue, Suite 5.70%
Neuberger Berman Group LLC 5.50%
State Street CorporationOne Congress Street, Suite 5.30%
Dimensional Fund Advisors LP6300 Bee Cave Road, Building One, Austin, TX 5.10%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Perrigo Company plc (PRGO) Latest News

4 Nov

Impact 3 · · GuruFocus.com
Impact 3 · · The Motley Fool transcript
Impact 3 · · Moby
Impact 3 · · PR Newswire

30 Oct

Impact 3 · · just-food.com

29 Oct

Impact 4 · · PR Newswire

28 Oct

Impact 3 · · Zacks

21 Oct

Impact 3 · · Zacks

16 Oct

Impact 3 · · Simply Wall St.

25 Sep

Impact 3 · · Zacks

12 Aug

Impact 3 · · The Motley Fool transcript

9 Aug

Impact 3 ·

8 Aug

Impact 3 · · MarketBeat transcript
Impact 3 ·

6 Aug

Impact 3 ·

5 Aug

Impact 3 · · Moby transcript
Impact 3 · transcript
Impact 3 ·
Impact 3 ·

9 Jun

Impact 3 · · Simply Wall St.

7 May

Impact 4 · · Simply Wall St.
Impact 4 · · Moby
Impact 3 · · Zacks

6 May

Impact 4 · · Zacks
Impact 3 · · PR Newswire

5 May

Impact 4 · · Simply Wall St.

30 Apr

Impact 4 · · PR Newswire

1 Apr

Impact 3 · · Insider Monkey

7 Mar

Impact 4 · · Simply Wall St.

28 Feb

Impact 4 · · MarketBeat

PRGO metrics, ten years each

stockrow.com/PRGO · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com